Amundi lifted its position in Prestige Consumer Healthcare Inc. (NYSE:PBH - Free Report) by 187.4% during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 25,669 shares of the company's stock after buying an additional 16,737 shares during the period. Amundi owned approximately 0.05% of Prestige Consumer Healthcare worth $1,909,000 as of its most recent filing with the Securities and Exchange Commission (SEC).
Several other large investors also recently modified their holdings of the company. Kestra Investment Management LLC bought a new stake in shares of Prestige Consumer Healthcare during the 4th quarter valued at about $27,000. Huntington National Bank grew its position in Prestige Consumer Healthcare by 39.9% during the third quarter. Huntington National Bank now owns 635 shares of the company's stock valued at $46,000 after buying an additional 181 shares during the period. GAMMA Investing LLC increased its holdings in Prestige Consumer Healthcare by 18.9% during the fourth quarter. GAMMA Investing LLC now owns 1,383 shares of the company's stock valued at $108,000 after buying an additional 220 shares during the last quarter. Blue Trust Inc. raised its position in Prestige Consumer Healthcare by 24.8% in the fourth quarter. Blue Trust Inc. now owns 2,190 shares of the company's stock worth $158,000 after acquiring an additional 435 shares during the period. Finally, KBC Group NV raised its position in Prestige Consumer Healthcare by 28.3% in the fourth quarter. KBC Group NV now owns 2,048 shares of the company's stock worth $160,000 after acquiring an additional 452 shares during the period. Institutional investors own 99.95% of the company's stock.
Analyst Ratings Changes
Several equities research analysts have recently commented on the company. StockNews.com upgraded Prestige Consumer Healthcare from a "hold" rating to a "buy" rating in a research note on Tuesday. Oppenheimer lifted their price objective on Prestige Consumer Healthcare from $87.00 to $93.00 and gave the company an "outperform" rating in a research report on Thursday, February 13th. Raymond James upgraded shares of Prestige Consumer Healthcare to a "moderate buy" rating in a research note on Thursday, December 19th. Canaccord Genuity Group upped their price target on shares of Prestige Consumer Healthcare from $93.00 to $100.00 and gave the stock a "buy" rating in a research report on Friday, February 7th. Finally, Sidoti downgraded shares of Prestige Consumer Healthcare from a "buy" rating to a "neutral" rating and set a $90.00 price objective on the stock. in a research report on Monday, December 9th. Three analysts have rated the stock with a hold rating and four have assigned a buy rating to the company's stock. According to data from MarketBeat.com, Prestige Consumer Healthcare has a consensus rating of "Moderate Buy" and a consensus price target of $93.33.
View Our Latest Report on PBH
Prestige Consumer Healthcare Price Performance
Shares of Prestige Consumer Healthcare stock traded down $0.24 on Friday, hitting $84.12. 622,921 shares of the company traded hands, compared to its average volume of 258,847. Prestige Consumer Healthcare Inc. has a 52 week low of $62.35 and a 52 week high of $90.04. The business has a 50-day simple moving average of $82.25 and a 200 day simple moving average of $78.53. The company has a debt-to-equity ratio of 0.56, a quick ratio of 2.20 and a current ratio of 3.68. The stock has a market capitalization of $4.17 billion, a P/E ratio of 19.70, a price-to-earnings-growth ratio of 2.69 and a beta of 0.46.
Prestige Consumer Healthcare (NYSE:PBH - Get Free Report) last announced its quarterly earnings results on Thursday, February 6th. The company reported $1.22 earnings per share for the quarter, topping the consensus estimate of $1.18 by $0.04. Prestige Consumer Healthcare had a net margin of 19.13% and a return on equity of 12.36%. Research analysts expect that Prestige Consumer Healthcare Inc. will post 4.5 earnings per share for the current fiscal year.
Insider Transactions at Prestige Consumer Healthcare
In related news, SVP Mary Beth Fritz sold 1,678 shares of Prestige Consumer Healthcare stock in a transaction dated Monday, March 10th. The stock was sold at an average price of $90.00, for a total value of $151,020.00. Following the completion of the transaction, the senior vice president now owns 17,157 shares in the company, valued at approximately $1,544,130. This trade represents a 8.91 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Insiders own 1.60% of the company's stock.
About Prestige Consumer Healthcare
(
Free Report)
Prestige Consumer Healthcare Inc, together with its subsidiaries, develops, manufactures, markets, distributes, and sells over-the-counter (OTC) health and personal care products in the United States and internationally. The company operates in two segments, North American OTC Healthcare and International OTC Healthcare.
Further Reading
Before you consider Prestige Consumer Healthcare, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Prestige Consumer Healthcare wasn't on the list.
While Prestige Consumer Healthcare currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know? MarketBeat just compiled its list of the twelve stocks that corporate insiders are abandoning. Complete the form below to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
